Wang H - Search Results

1

Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma.

Jiang L, Qin J, Dai Y, Zhao S, Zhan Q, Cui P, Ren L, Wang X, Zhang R, Gao C, Zhou Y, Cai S, Wang G, Xie W, Tang X, Shi M, Ma F, Liu J, Wang T, Wang C, Svrcek M, Bardier-Dupas A, Emile JF, de Mestier L, Bachet JB, Nicolle R, Cros J, Laurent-Puig P, Wei M, Song B, Jing W, Guo S, Zheng K, Jiang H, Wang H, Deng X, Chen H, Tian Q, Wang S, Shi S, Jin G, Yin T, Fang H, Chen S, Shen B. Jiang L, et al. Among authors: wang x, wang h, wang g, wang t, wang c, wang s. Nat Med. 2024 Mar;30(3):749-761. doi: 10.1038/s41591-023-02790-x. Epub 2024 Jan 29. Nat Med. 2024. PMID: 38287168

2

Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.

Guo S, Qin H, Liu K, Wang H, Bai S, Liu S, Shao Z, Zhang Y, Song B, Xu X, Shen J, Zeng P, Shi X, Chen H, Gao S, Xu J, Pan Y, Xiong L, Li F, Zhang D, Jiao X, Jin G. Guo S, et al. Among authors: wang h. Clin Transl Med. 2021 Sep;11(9):e520. doi: 10.1002/ctm2.520. Clin Transl Med. 2021. PMID: 34586739 Free PMC article.

3

Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases.

Zhang G, Li B, Yin X, Gao S, Shen S, Wang H, Shi X, Liu W, Zheng K, Jing W, Zhang Y, He T, Li G, Hu X, Guo S, Jin G. Zhang G, et al. Among authors: wang h. Int J Surg. 2022 Aug;104:106786. doi: 10.1016/j.ijsu.2022.106786. Epub 2022 Jul 19. Int J Surg. 2022. PMID: 35868619

4

Negative p53 Expression Confers Worse Prognosis in Patients With Resected Pancreatic Ductal Adenocarcinoma: Research Focused on Reinterpretation of Immunohistochemical Staining.

Li B, Wang Y, Wang J, Zhang G, Yin X, Wang H, Jiang H, Jin G, Guo S. Li B, et al. Among authors: wang h, wang j, wang y. Pancreas. 2022 Oct 1;51(9):1217-1224. doi: 10.1097/MPA.0000000000002175. Pancreas. 2022. PMID: 37078948

5

A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.

Guo SW, Shen J, Gao JH, Shi XH, Gao SZ, Wang H, Li B, Yuan WL, Lin L, Jin G. Guo SW, et al. Among authors: wang h. Surgery. 2020 Dec;168(6):1003-1014. doi: 10.1016/j.surg.2020.02.013. Epub 2020 Apr 19. Surgery. 2020. PMID: 32321665

6

Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.

Li B, Shen S, You S, Zhang G, Gao S, Shi X, Wang H, Yin X, Xu X, Guo S, Jin G. Li B, et al. Among authors: wang h. BMC Cancer. 2021 May 26;21(1):612. doi: 10.1186/s12885-021-08380-9. BMC Cancer. 2021. PMID: 34034684 Free PMC article.

7

Identification and functional analysis of heterogeneous FOXP3⁺ Treg cell subpopulations in human pancreatic ductal adenocarcinoma.

Yi G, Guo S, Liu W, Wang H, Liu R, Tsun A, Jin G, Li B. Yi G, et al. Among authors: wang h. Sci Bull (Beijing). 2018 Aug 15;63(15):972-981. doi: 10.1016/j.scib.2018.05.028. Epub 2018 May 30. Sci Bull (Beijing). 2018. PMID: 36658893

8

A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma.

Zhu L, Shen S, Wang H, Zhang G, Yin X, Shi X, Gao S, Han J, Ren Y, Wang J, Jiang H, Guo S, Jin G. Zhu L, et al. Among authors: wang h, wang j. BMC Cancer. 2023 Aug 23;23(1):790. doi: 10.1186/s12885-023-11181-x. BMC Cancer. 2023. PMID: 37612635 Free PMC article.

9

Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity.

Shi X, Li Y, Yuan Q, Tang S, Guo S, Zhang Y, He J, Zhang X, Han M, Liu Z, Zhu Y, Gao S, Wang H, Xu X, Zheng K, Jing W, Chen L, Wang Y, Jin G, Gao D. Shi X, et al. Among authors: wang h, wang y. Nat Commun. 2022 Apr 21;13(1):2169. doi: 10.1038/s41467-022-29857-6. Nat Commun. 2022. PMID: 35449156 Free PMC article.

10

Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer.

Guo S, Gao S, Liu R, Shen J, Shi X, Bai S, Wang H, Zheng K, Shao Z, Liang C, Peng S, Jin G. Guo S, et al. Among authors: wang h. FASEB J. 2019 Jan;33(1):873-884. doi: 10.1096/fj.201800617R. Epub 2018 Aug 9. FASEB J. 2019. PMID: 30091943

We concluded that tumor size and mutated VEGF pathway in PC are important factors affecting PDX model construction with NSG mice.-Guo, S., Gao, S., Liu, R., Shen, J., Shi, X., Bai, S., Wang, H., Zheng, K., Shao, Z., Liang, C., Peng, S., Jin, G. Oncological and genet …

We concluded that tumor size and mutated VEGF pathway in PC are important factors affecting PDX model construction with NSG mice.-Guo, S., G …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

140,224 results

Search Page